This MedLibrary.org supplementary page on Albendazole is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Albendazole
|
|
| Systematic (IUPAC) name | |
| methyl [(5-propylsulfanyl-3H- benzoimidazol-2-yl) amino]formate | |
| Identifiers | |
| CAS number | |
| ATC code | P02 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C12H15N3O2S |
| Mol. mass | 265.333 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | oxidation of sulfur atom to sulfoxide, the active metabolite |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
D |
| Legal status |
prescription |
| Routes | only oral route |
Albendazole, marketed as Albenza, Eskazole or Zentel, is a member of the benzimidazole compounds used as a drug indicated for the treatment of a variety of worm infestations. Although this use is widespread in the United States, the FDA has not approved albendazole for this indication.
Contents |
Uses
It is effective against
In Africa, albendazole (donated by GlaxoSmithKline) is being used to treat lymphatic filariasis as part of efforts to stop transmission of the disease.[1] In sub-Saharan Africa, albendazole is used in conjunction with ivermectin, and elsewhere in the world, the medicine is used in combination with diethylcarbamazine.[1]
Mode of action
Vermicidal: Albendazole (C12H15N3O2S) causes degenerative alterations in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules. The loss of the cytoplasmic microtubules leads to impaired uptake of glucose by the larval and adult stages of the susceptible parasites, and depletes their glycogen stores. Degenerative changes in the endoplasmic reticulum, the mitochondria of the germinal layer, and the subsequent release of lysosomes result in decreased production of adenosine triphosphate (ATP), which is the energy required for the survival of the helminth. Due to diminished energy production, the parasite is immobilized and eventually dies.
Albendazole also has been shown to inhibit the enzyme fumarate reductase, which is helminth-specific. This action may be considered secondary to the effect on the microtubules due to the decreased absorption of glucose. This action occurs in the presence of reduced amounts of nicotinamide-adenine dinucleotide in reduced form (NADH), which is a coenzyme involved in many cellular oxidation-reduction reactions.
Albendazole has larvicidal effects in necatoriasis and ovicidal effects in ascariasis, ancylostomiasis, and trichuriasis.
Pregnancy class
D (Australia) - Do not take when pregnant, and do not become pregnant for one month after taking this drug.
Dosage
Hydatid disease:
- Patients 60 kg or greater: 400 mg twice daily, with meals.
- Patients less than 60 kg: 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg).
- Treatment interval: 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles.
NOTE: When administering albendazole in the pre- or post-surgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.
Neurocysticerosis:
- Patients 60 kg or greater: 400 mg twice daily, with meals.
- Patients less than 60 kg: 15 mg/kg/day given in divided doses twice daily with meals (maximum total daily dose 800 mg).
- Treatment interval: 8-30 days.
Note: Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy as required. Oral or intravenous corticosteroids should be considered to prevent cerebral hypertensive episodes during the first week of treatment.
Contraindications
- Hypersensitivity to the benzimidazole class of compounds.
References
- ^ a b The Carter Center, "Lymphatic Filariasis Elimination Program", <http://www.cartercenter.org/health/lf/index.html>. Retrieved on 17 July 2008
External links
See also
|
|||||||||||
Wikipedia content modification information:
- This page was last modified on 21 July 2008, at 14:28.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Albendazole".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.